Skip to main content
. 2017 Feb 2;116(6):775–784. doi: 10.1038/bjc.2017.15

Figure 1.

Figure 1

Correlation of ASPN mRNA with BCR in the prostate cancer patient cohort described by Mortensen et al (2015). (A) A significant increase in ASPN transcripts was observed in tumour vs patient matched benign samples; mean ASPN mRNA levels of 7.0 in tumour samples vs 5.3 in benign samples (t-test, P<0.001). (B) Kaplan–Meier analysis correlated higher ASPN transcript levels with shorter time to biochemical recurrence (P=0.0011) in the Mortensen et al (2015) data set. The lower panel shows the number of patients at risk of BCR during 80 months of follow up.